A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 945-946, Issue , 2014, Pages 225-232

  Bennetto Hood, Chantelle ^a   Tabolt, Glenn ^b   Savina, Paul ^b   Acosta, Edward P ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Dolutegravir; HIV; Human; Integrase inhibitor; Mass spectrometry

Indexed keywords

DISEASES; ISOTOPES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA (HUMAN);

CLINICAL PHARMACOKINETICS; COEFFICIENT OF DETERMINATION; DOLUTEGRAVIR; HIV; HUMAN; INTEGRASE; SENSITIVE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

CALIBRATION;

ABACAVIR; ACETONITRILE; ACICLOVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; GANCICLOVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TENOFOVIR; WATER; ZALCITABINE; ZIDOVUDINE;

ACCURACY; ANALYTIC METHOD; ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; PRECIPITATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ACETONITRILE; ACN; ANTIRETROVIRALS; AREA UNDER THE CONCENTRATION-TIME CURVE; ARVS; AUC; COEFFICIENT OF VARIATION; CV; DIMETHYL SULFOXIDE; DMSO; DOLUTEGRAVIR; DTG; EDTA; EFAVIRENZ; EFV; ELVITEGRAVIR; ETHYLENEDIAMINE TETRAACETIC ACID; EVG; HIV; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INSTI; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; INTERNAL STANDARD; IPA; IS; ISOPROPANOL; LC-MS/MS; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; LLOQ; LOWER LIMIT OF QUANTITATION; MASS SPECTROMETRY; MEOH; METHANOL; MRM; MULTI REACTION MONITORING; NRTI; NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHARMACOKINETIC; PK; QC; QUALITY CONTROL; RAL; RALTEGRAVIR; UDP-GLUCURONOSYL TRANSFERASE 1A1; UGT1A1; ULQ; UPPER LIMIT OF QUANTITATION;

CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; LIMIT OF DETECTION; TANDEM MASS SPECTROMETRY;

EID: 84890841567     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2013.11.054     Document Type: Article

References (15)

1. Pommier Y., Johnson A., Marchland C. Nat. Rev. Drug Discov. 2005, 4:236.
2. Katlama C., Murphy R. Opin. Investig. Drugs 2012, 21:523.
3. van Lunzen J., Maggiolo F., Arribas R., Rakhmanova A., Yeni P., Young B., Rockstroh J., Almond S., Song I., Brothers C., Min S. Lancet Infect. Dis. 2012, 12:111.
4. Raffi F., Rachlis A., Stellbrink H.J., Hardy W.D., Torti C., Orkin C., Bloch M., Podzamczer D., Pokrovsky V., Pulido F., Almond S., Margolis D., Brennan C., Min S. Lancet 2013, 381:735.
5. Walmsley S., et al. Dolutegravir (DTG; S/GSK1349572)+abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results - SINGLE (ING114467). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012, (abstract H-556b).
6. Cahn P., Pozniak A.L., Mingrone H., Khuldyakov A., Brites C., Andrade-Villanueva J.F., Richmond G., Buendia C.B., Fourie J., Ramgopal M., Hagins D., Felizarta F., Madruga J., Reuter T., Newman T., Small C.B., Lombaard J., Grinsztejn B., Dorey D., Underwood M., Griffith S., Min S. Lancet 2013, on behalf of the extended SAILING Study Team, July 2. pii: S0140-6736(13)61221-0 [Epub ahead of print]. 10.1016/S0140-6736(13)61221-0.
7. Underwood R., Johns B., Sato A., Martin J., Deeks S., Fujiwara T. J. Acquir. Immune Defic. Syndr. 2012, 61:297.
8. Eron J.J., Clotet B., Durant J., Katlama C., Kumar P., Lazzarin A., Poizot-Martin I., Richmond G., Soriano V., Ait-Khaled M., Fujiwara T., Huang J., Min S., Vavro C., Yeo J. J. Infect. Dis. 2013, 207:740. for the VIKING Study Group.
9. Reese M.J., Savina P.M., Generaux G.T., Tracy H., Humphreys J.E., Kanaoka E., Webster L.O., Harmon K.A., Clarke J.D., Polli J.W. Drug Metab. Dispos. 2013, 41:353.
10. Castellino S., Moss L., Wagner D., Borland J., Song I., Shuguang C., Lou Y., Min S.S., Goljer I., Culp A., Piscitelli S.C., Savina P.M. Antimicrob. Agents Chemother. 2013, May [Epub ahead of print].
11. Song I., Borland J., Chen S., Lou Y., Peppercorn A., Wajima T., Min S., Piscitelli S.C. Br. J. Clin. Pharmacol. 2011, 72:103.
12. Min S., Song I., Borland J., Chen S., Lou Y., Fujiwara T., Piscitelli S.C. Antimicrob. Agents Chemother. 2010, 54:254.
13. Patel P., Song I., Borland J., Patel A., Lou Y., Chen S., Wajima T., Peppercorn A., Min S.S., Piscitelli S.C. J. Antimicrob. Chemother. 2011, 66:1567.
14. Song I., Borland J., Min S., Lou Y., Chen S., Patel 'P, Wajima T., Piscitelli S.C. Antimicrob. Agents Chemother. 2011, 66:3517.
15. Food and Drug Administration Guidance for Industry; Bioanalytical Method Validation 2001, US Department of Health and Human Services, CDER and CVM, Rockville, MD, May.